Biotech NALIA Systems Gain Traction on Syndicate Room with Individual Investor Support

NALIA Systems has created a point-of-care, lab-grade diagnostics array that delivers results in 20 minutes which  gives doctors the in-house tools required to diagnose certain diseases from within their surgery. Although still in prototype mode, a first customer has already been secured. In addition to this potentially disruptive technology, NALIA also has an already established a revenue-generating service, which creates tests for diseases that require custom arrays.

With nearly half of the round already raised on Syndicate Room— over £236,608 — NALIA is looking to close this round to fund growth of the existing, revenue-making side of the business and develop the point of care system. With a pre-money valuation of £1,833,338, NALIA is seeking to raise £399,996 on this round.  Share prices are listed at £13.91. This week, investor Ian Armitage, who has contributed £100,000 to the round, announced plans to add another £50,000 before the round closes.

“Before investing in NALIA Systems I did a lot of due diligence including studying and following their business plan and the technology, discussing it with the inventors and scientists working on the project, and visiting their laboratory at Middlesex University,” commented Armitage. “In my opinion NALIA has an outstanding solution for rapid point-of-care diagnosis of a wide range of conditions, such as autoimmune diseases, allergies, infectious diseases and cancers, as well as prospects for diagnostics and testing outside point-of-care situations. I am greatly encouraged that NALIA is already generating revenue. I have invested £100,000 in NALIA Systems and am planning to invest another £50,000 before the SyndicateRoom round closes.”

NALIA Systems was cofounded by Chief Scientist Ivan Roitt, an internationally renowned expert in immunology, and Chief Clinical Advisor Ian Cree, an expert in the clinical adoption of diagnostic products. They are supported by an experienced team and are led by CEO Nigel Davis, who has 24 years of experience across organizations including Glaxo Group Research and Innovir UK.